Hepatitis E vaccine to prevent morbidity and mortality during epidemics

Kenrad Edwin Nelson, James W K Shih, Jun Zhang, Qinjian Zhao, Ningshao Xia, John R Ticehurst, Alain B Labrique

Research output: Contribution to journalArticle

Abstract

Recurrent, large, waterborne epidemics of hepatitis E virus (HEV) occur regularly after monsoon rains contaminate water supplies in Asia or during humanitarian crises in Africa. These epidemics commonly affect thousands of persons, and it has a high mortality in pregnant women who become infected. Although a subunit HEV vaccine has been developed by Chinese investigators and was found to be highly effective and safe in a large clinical trial, this vaccine is only available in China. Until it is prequalified by the World Health Organization, the vaccine may not be available for use outside of China in low-income countries that lack national vaccine regulatory agencies. In this manuscript, we explore possible strategies for providing access to this potentially important vaccine for international use in responding to epidemics of HEV in low-resource countries.

Original languageEnglish (US)
Article numberofu098
JournalOpen Forum Infectious Diseases
Volume1
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Hepatitis E
Hepatitis E virus
Vaccines
Morbidity
Mortality
China
Rain
Water Supply
Pregnant Women
Research Personnel
Clinical Trials

Keywords

  • Hepatitis E virus
  • Humanitarian emergencies
  • Waterborne epidemics
  • World Health Organization

ASJC Scopus subject areas

  • Oncology
  • Clinical Neurology

Cite this

Hepatitis E vaccine to prevent morbidity and mortality during epidemics. / Nelson, Kenrad Edwin; Shih, James W K; Zhang, Jun; Zhao, Qinjian; Xia, Ningshao; Ticehurst, John R; Labrique, Alain B.

In: Open Forum Infectious Diseases, Vol. 1, No. 3, ofu098, 2014.

Research output: Contribution to journalArticle

@article{f9cf53442cc94342a1a4abe5323fe68c,
title = "Hepatitis E vaccine to prevent morbidity and mortality during epidemics",
abstract = "Recurrent, large, waterborne epidemics of hepatitis E virus (HEV) occur regularly after monsoon rains contaminate water supplies in Asia or during humanitarian crises in Africa. These epidemics commonly affect thousands of persons, and it has a high mortality in pregnant women who become infected. Although a subunit HEV vaccine has been developed by Chinese investigators and was found to be highly effective and safe in a large clinical trial, this vaccine is only available in China. Until it is prequalified by the World Health Organization, the vaccine may not be available for use outside of China in low-income countries that lack national vaccine regulatory agencies. In this manuscript, we explore possible strategies for providing access to this potentially important vaccine for international use in responding to epidemics of HEV in low-resource countries.",
keywords = "Hepatitis E virus, Humanitarian emergencies, Waterborne epidemics, World Health Organization",
author = "Nelson, {Kenrad Edwin} and Shih, {James W K} and Jun Zhang and Qinjian Zhao and Ningshao Xia and Ticehurst, {John R} and Labrique, {Alain B}",
year = "2014",
doi = "10.1093/ofid/ofu098",
language = "English (US)",
volume = "1",
journal = "Open Forum Infectious Diseases",
issn = "2328-8957",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Hepatitis E vaccine to prevent morbidity and mortality during epidemics

AU - Nelson, Kenrad Edwin

AU - Shih, James W K

AU - Zhang, Jun

AU - Zhao, Qinjian

AU - Xia, Ningshao

AU - Ticehurst, John R

AU - Labrique, Alain B

PY - 2014

Y1 - 2014

N2 - Recurrent, large, waterborne epidemics of hepatitis E virus (HEV) occur regularly after monsoon rains contaminate water supplies in Asia or during humanitarian crises in Africa. These epidemics commonly affect thousands of persons, and it has a high mortality in pregnant women who become infected. Although a subunit HEV vaccine has been developed by Chinese investigators and was found to be highly effective and safe in a large clinical trial, this vaccine is only available in China. Until it is prequalified by the World Health Organization, the vaccine may not be available for use outside of China in low-income countries that lack national vaccine regulatory agencies. In this manuscript, we explore possible strategies for providing access to this potentially important vaccine for international use in responding to epidemics of HEV in low-resource countries.

AB - Recurrent, large, waterborne epidemics of hepatitis E virus (HEV) occur regularly after monsoon rains contaminate water supplies in Asia or during humanitarian crises in Africa. These epidemics commonly affect thousands of persons, and it has a high mortality in pregnant women who become infected. Although a subunit HEV vaccine has been developed by Chinese investigators and was found to be highly effective and safe in a large clinical trial, this vaccine is only available in China. Until it is prequalified by the World Health Organization, the vaccine may not be available for use outside of China in low-income countries that lack national vaccine regulatory agencies. In this manuscript, we explore possible strategies for providing access to this potentially important vaccine for international use in responding to epidemics of HEV in low-resource countries.

KW - Hepatitis E virus

KW - Humanitarian emergencies

KW - Waterborne epidemics

KW - World Health Organization

UR - http://www.scopus.com/inward/record.url?scp=84978328070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978328070&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofu098

DO - 10.1093/ofid/ofu098

M3 - Article

C2 - 25734166

AN - SCOPUS:84978328070

VL - 1

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

SN - 2328-8957

IS - 3

M1 - ofu098

ER -